METHODS FOR SCREENING MUSCLE INVASIVE BLADDER CANCER PATIENTS FOR NEOADJUVANT CHEMOTHERAPY RESPONSIVENESS

摘要

Systems and methods for determining whether a muscle-invasive bladder cancer patient may respond to neoadjuvant chemotherapy based on identifying alterations in the ATM, Rb, FANCC, MTOR, PIK3C3, MYCN, CDKN2B, MLL2, NOTCH3, APC, NF1, and/or KDR genes in the patient are provided. If a patient has such alterations, the patient may be administered neoadjuvant chemotherapy prior to surgical bladder removal or bladder preservation therapy. If a patient does not have such alterations, the patient is not administered neoadjuvant chemotherapy prior to surgical bladder removal or bladder preservation therapy.

主权项

1. A method, comprising determining whether one or more of the ataxia telangiectasia mutated (ATM) gene, the retinoblastoma (Rb) gene, or the Fanconi anemia group C (FANCC) gene in muscle-invasive bladder cancer (MIBC) tissue isolated from a MIBC patient includes one or more alterations encoding an ATM protein, Rb protein, or FANCC protein, respectively, having inhibited biologic activity; if it is determined that one or more of the ATM gene, the Rb gene, or the FANCC gene includes said alterations, treating the MIBC patient with a neoadjuvant chemotherapy regimen prior to surgically removing the urinary bladder or treating the MIBC patient with a neoadjuvant chemotherapy regimen prior to or contemporaneously with a bladder preservation treatment regimen, and if it is determined that one or more of the ATM gene, the Rb gene, or the FANCC gene does not include said alterations, treating the MIBC patient by surgically removing the urinary bladder or with a bladder preservation treatment regimen, but not treating the patient with a neoadjuvant chemotherapy regimen.